CSP CERTIFIED QUALITY EXAM UPDATED 2025/26 TEST
SPECIALTY PHARMACY WITH ACCURATE DETAILED SOLUTIONS
A+ SCORE SOLUTION REVIEW
Which oral chemotherapy cycle would be considered incorrect?
A. Revlimid (lenalidomide) 25mg daily for 21 days, then 7 days off
B. Ibrance (palbociclib) 125mg daily for 21 days, then 7 days off
C. Afinitor (everolimus) 10mg daily for 21 days, then 7 days off
D. Temodar (temozolomide) 150mg/m2 daily for 5 days every 28
days - --ANSWERS---c. Afinitor (everolimus) 10mg daily for 21
days, then 7 days off
Grapefruit and grapefruit juice should be avoided when taking all
of the following oral
Chemotherapy agents EXCEPT
A. Imbruvica (ibrutinib)
B. Gleevec (imatinib)
C. Sutent (sunitinib)
D. Zytiga (abiraterone acetate) - --ANSWERS---d. Zytiga
(abiraterone acetate)
Which of the following recommendations would be most
appropriate when discussing a change
In therapy from Exjade (deferasirox) to Jadenu (deferasirox) with
a healthcare provider?
A. There is no need to monitor renal function with Jadenu
B. The Jadenu dose should be started at a dosage 30% less than
current Exjade dose
C. Dosing is based on equivalent mg/kg dosing parameters
D. The Jadenu dose should be started at a dosage 30% more than
current Exjade dose - --ANSWERS---b. The Jadenu dose should
be started at a dosage 30% less than current Exjade dose
,A 56 y/o M is diagnosed with metastatic, castration‐resistant
prostate cancer and the provider
Asks which oral antiandrogen you recommend. He has a past
medical history including
Hypertension and poorly controlled type II diabetes. What is your
recommendation?
A. Zytiga (abiraterone acetate) 1000mg once daily with
prednisone
B. Xtandi (enzalutamide) 160mg once daily with prednisone
C. Xtandi (enzalutamide) 160mg once daily
D. Zytiga (abiraterone acetate) 1000mg once daily - --ANSWERS-
--c. Xtandi (enzalutamide) 160mg once daily
Which of these medications is NOT a Celgene product requiring a
patient to be enrolled in the
Manufacturer REMS program?
A. Ninlaro (ixazomib)
B. Thalomid (thalidomide)
C. Pomalyst (pomalidomide)
D. Revlimid (lenalidomide) - --ANSWERS---a. Ninlaro (ixazomib)
All of the following medications have a FDA approved indication
for renal cell carcinoma except:
A. Cabometyx (cabozantinib)
B. Afinitor (everolimus)
C. Sutent (sunitinib)
D. Nexavar (sorafenib)
E. Mekinist (trametinib) - --ANSWERS---e. Mekinist (trametinib)
Which of the following tyrosine kinase inhibitors have a black box
warning for arterial
Thrombosis?
, A. Sprycel (dasatinib)
B. Iclusig (ponatinib)
C. Bosulif (bosutinib)
D. Gleevec (imatinib)
E. Tasigna (nilotinib) - --ANSWERS---b. Iclusig (ponatinib)
A patient in your clinic has a new diagnosis of chronic phase
Philadelphia chromosome positive
CML and the provider wants to order treatment with Tasigna
(nilotinib). During your drug
Review, you notice the patient is on fluconazole. Which of the
following is true regarding the
Interaction between Tasigna and fluconazole?
A. There is no interaction, no change is necessary
B. Fluconazole may increase Tasigna concentrations and should
be monitored
C. Fluconazole may increase Tasigna concentrations and is
contraindicated
D. Fluconazole may decrease Tasigna concentrations and in
contraindicated - --ANSWERS---c. Fluconazole may increase
Tasigna concentrations and is contraindicated
A provider wants to begin a patient on maintenance dosing for
Temodar (temozolomide) and
Wants you to calculate the correct dose. You calculate the
patient's BSA to be 1.67m2. What
Dose do you recommend?
A. 125.25mg (rounded up to 140mg capsule)‐ 1 capsule PO qday x
42 days
B. 250.5mg (rounded down to 250mg capsule)‐ 1 capsule PO qday
x 5days of a 28 day cycle
C. 125.25mg (rounded up to 140mg capsule)‐ 1 capsule PO qday x
5 days of a 28 day cycle
SPECIALTY PHARMACY WITH ACCURATE DETAILED SOLUTIONS
A+ SCORE SOLUTION REVIEW
Which oral chemotherapy cycle would be considered incorrect?
A. Revlimid (lenalidomide) 25mg daily for 21 days, then 7 days off
B. Ibrance (palbociclib) 125mg daily for 21 days, then 7 days off
C. Afinitor (everolimus) 10mg daily for 21 days, then 7 days off
D. Temodar (temozolomide) 150mg/m2 daily for 5 days every 28
days - --ANSWERS---c. Afinitor (everolimus) 10mg daily for 21
days, then 7 days off
Grapefruit and grapefruit juice should be avoided when taking all
of the following oral
Chemotherapy agents EXCEPT
A. Imbruvica (ibrutinib)
B. Gleevec (imatinib)
C. Sutent (sunitinib)
D. Zytiga (abiraterone acetate) - --ANSWERS---d. Zytiga
(abiraterone acetate)
Which of the following recommendations would be most
appropriate when discussing a change
In therapy from Exjade (deferasirox) to Jadenu (deferasirox) with
a healthcare provider?
A. There is no need to monitor renal function with Jadenu
B. The Jadenu dose should be started at a dosage 30% less than
current Exjade dose
C. Dosing is based on equivalent mg/kg dosing parameters
D. The Jadenu dose should be started at a dosage 30% more than
current Exjade dose - --ANSWERS---b. The Jadenu dose should
be started at a dosage 30% less than current Exjade dose
,A 56 y/o M is diagnosed with metastatic, castration‐resistant
prostate cancer and the provider
Asks which oral antiandrogen you recommend. He has a past
medical history including
Hypertension and poorly controlled type II diabetes. What is your
recommendation?
A. Zytiga (abiraterone acetate) 1000mg once daily with
prednisone
B. Xtandi (enzalutamide) 160mg once daily with prednisone
C. Xtandi (enzalutamide) 160mg once daily
D. Zytiga (abiraterone acetate) 1000mg once daily - --ANSWERS-
--c. Xtandi (enzalutamide) 160mg once daily
Which of these medications is NOT a Celgene product requiring a
patient to be enrolled in the
Manufacturer REMS program?
A. Ninlaro (ixazomib)
B. Thalomid (thalidomide)
C. Pomalyst (pomalidomide)
D. Revlimid (lenalidomide) - --ANSWERS---a. Ninlaro (ixazomib)
All of the following medications have a FDA approved indication
for renal cell carcinoma except:
A. Cabometyx (cabozantinib)
B. Afinitor (everolimus)
C. Sutent (sunitinib)
D. Nexavar (sorafenib)
E. Mekinist (trametinib) - --ANSWERS---e. Mekinist (trametinib)
Which of the following tyrosine kinase inhibitors have a black box
warning for arterial
Thrombosis?
, A. Sprycel (dasatinib)
B. Iclusig (ponatinib)
C. Bosulif (bosutinib)
D. Gleevec (imatinib)
E. Tasigna (nilotinib) - --ANSWERS---b. Iclusig (ponatinib)
A patient in your clinic has a new diagnosis of chronic phase
Philadelphia chromosome positive
CML and the provider wants to order treatment with Tasigna
(nilotinib). During your drug
Review, you notice the patient is on fluconazole. Which of the
following is true regarding the
Interaction between Tasigna and fluconazole?
A. There is no interaction, no change is necessary
B. Fluconazole may increase Tasigna concentrations and should
be monitored
C. Fluconazole may increase Tasigna concentrations and is
contraindicated
D. Fluconazole may decrease Tasigna concentrations and in
contraindicated - --ANSWERS---c. Fluconazole may increase
Tasigna concentrations and is contraindicated
A provider wants to begin a patient on maintenance dosing for
Temodar (temozolomide) and
Wants you to calculate the correct dose. You calculate the
patient's BSA to be 1.67m2. What
Dose do you recommend?
A. 125.25mg (rounded up to 140mg capsule)‐ 1 capsule PO qday x
42 days
B. 250.5mg (rounded down to 250mg capsule)‐ 1 capsule PO qday
x 5days of a 28 day cycle
C. 125.25mg (rounded up to 140mg capsule)‐ 1 capsule PO qday x
5 days of a 28 day cycle
